Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

995
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
995
Cancer Therapies02:49

Cancer Therapies

10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

755
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
755
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

701
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
701
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation Between Hemoglobin Levels with Muscle Function and the Risk of Sarcopenia in Patients with Cancer of the Digestive System: A Cross-Sectional Study.

Muscles (Basel, Switzerland)·2026
Same author

Current application and future directions for the sarcopenic obesity Global Leadership Initiative (SOGLI) diagnostic algorithm.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Efficacy of Mediterranean diet for the primary prevention of oncological diseases: A systematic review and meta-analysis featured in the Italian National Guidelines "La Dieta Mediterranea".

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

Mediterranean diet in cancer patients' survival: A systematic review and meta-analysis for tertiary prevention featured in the Italian National Guidelines "La Dieta Mediterranea".

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

Avoiding the collapse of the Tower of Babel in nutritional care.

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

Nutrition reviews·2026

Related Experiment Video

Updated: Mar 9, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K

Sarcopenia and chemotherapy-mediated toxicity.

Maria Cecília Monteiro Dela Vega1, Alessandro Laviano2, Gustavo Duarte Pimentel3

  • 1Centro Brasileiro de Radioterapia, Oncologia e Mastologia, Goiânia, GO, Brazil.

Einstein (Sao Paulo, Brazil)
|January 12, 2017
PubMed
Summary

Sarcopenia, the loss of muscle mass, significantly reduces survival in cancer patients by affecting treatment adherence and dosage. This condition also increases healthcare costs, highlighting its importance in cancer care.

More Related Videos

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
13:35

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

12.0K

Related Experiment Videos

Last Updated: Mar 9, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K
Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
13:35

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

12.0K

Area of Science:

  • Oncology
  • Geriatrics
  • Clinical Nutrition

Background:

  • Sarcopenia is a prevalent condition in cancer patients.
  • Chemotherapy can exacerbate muscle loss and toxicity.
  • The interplay between sarcopenia and treatment outcomes is critical.

Purpose of the Study:

  • To review the impact of sarcopenia on cancer patient outcomes.
  • To examine the relationship between sarcopenia and chemotherapy-induced toxicity.
  • To highlight sarcopenia as a prognostic factor and cost determinant.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of studies on sarcopenia in cancer.
  • Synthesis of evidence on treatment toxicity and survival.

Main Results:

  • Sarcopenia is consistently linked to decreased overall survival in cancer patients.
  • Sarcopenia influences treatment discontinuation and dose reduction.
  • Increased healthcare costs are associated with sarcopenia in this population.

Conclusions:

  • Sarcopenia is a significant negative prognostic factor in cancer.
  • Early identification and management of sarcopenia are crucial for improving patient outcomes.
  • Addressing sarcopenia can potentially reduce healthcare expenditures.